Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Nov 1;196(9):1144-1151.
doi: 10.1164/rccm.201610-2172OC.

Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results

Noah Lechtzin  1 , Nicole Mayer-Hamblett  2   3 , Natalie E West  1 , Sarah Allgood  1 , Ellen Wilhelm  2 , Umer Khan  3 , Moira L Aitken  2 , Bonnie W Ramsey  2   3 , Michael P Boyle  1   4 , Peter J Mogayzel Jr  1 , Ronald L Gibson  2   3 , David Orenstein  5 , Carlos Milla  6 , John P Clancy  7 , Veena Antony  8 , Christopher H Goss  2   3 ; eICE Study Team
Collaborators, Affiliations
Randomized Controlled Trial

Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations. eICE Study Results

Noah Lechtzin et al. Am J Respir Crit Care Med. .

Abstract

Rationale: Individuals with cystic fibrosis (CF) experience frequent acute pulmonary exacerbations, which lead to decreased lung function and reduced quality of life.

Objectives: The goal of this study was to determine if an intervention directed toward early detection of pulmonary exacerbations using home spirometry and symptom monitoring would result in slower decline in lung function than in control subjects.

Methods: We conducted a multicenter, randomized trial at 14 CF centers with subjects at least 14 years old. The early intervention arm subjects measured home spirometry and symptoms electronically twice per week. Sites were notified if a participant met criteria for an exacerbation and contacted participants to determine if treatment for acute exacerbation was required. Participants in the usual care arm were seen every 3 months and were asked to contact the site if they were concerned about worsening pulmonary symptoms.

Measurements and main results: The primary outcome was the 52-week change in FEV1. Secondary outcomes included time to first exacerbation and subsequent exacerbation, quality of life, and change in weight. A total of 267 patients were randomized, and the study arms were well matched at baseline. There was no significant difference between study arms in 52-week mean change in FEV1 slope (mean slope difference, 0.00 L, 95% confidence interval, -0.07 to 0.07; P = 0.99). The early intervention arm subjects detected exacerbations more frequently than usual care arm subjects (time to first exacerbation hazard ratio, 1.45; 95% confidence interval, 1.09 to 1.93; P = 0.01). Adverse events were not significantly different between treatment arms.

Conclusions: An intervention of home monitoring among patients with CF was able to detect more exacerbations than usual care, but this did not result in slower decline in lung function. Clinical trial registered with www.clinicaltrials.gov (NCT01104402).

Keywords: clinical trial; cystic fibrosis; home monitoring; pulmonary exacerbation.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Consolidated Standards of Reporting Trials diagram showing participant flow in the eICE (Early Intervention in Cystic Fibrosis Exacerbation) study. ITT = intention-to-treat; PP = per protocol.
Figure 2.
Figure 2.
(A) Mean absolute change from baseline in FEV1. (B) Mean absolute change from baseline in body mass index. Data are presented as means and 95% confidence intervals. BMI = body mass index; EI = early intervention; UC = usual care.
See this image and copyright information in PMC

Comment in

References

    1. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, Elbert A, Petren KM, Marshall BC. The Cystic Fibrosis Foundation patient registry: design and methods of a national observational disease registry. Ann Am Thorac Soc. 2016;13:1173–1179. - PubMed
    1. Cystic Fibrosis Foundation. Bethesda, MD: Cystic Fibrosis Foundation; 2014. Cystic Fibrosis Foundation patient registry: 2013 annual report.
    1. MacKenzie T, Gifford AH, Sabadosa KA, Quinton HB, Knapp EA, Goss CH, Marshall BC. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014;161:233–241. - PMC - PubMed
    1. Liou TG, Adler FR, Fitzsimmons SC, Cahill BC, Hibbs JR, Marshall BC. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol. 2001;153:345–352. - PMC - PubMed
    1. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med. 2005;171:1053–1059. - PubMed

Publication types

Associated data